Carisma Therapeutics INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
Carisma Therapeutics Inc. reported Q3 2025 results, confirming its strategic shift to an orderly wind-down of operations after a failed merger and Nasdaq delisting.
OTC.Pink
Carisma Therapeutics reports Q2 2025 results, detailing a planned merger with OrthoCellix, significant operational wind-down, and ongoing Nasdaq compliance challenges.
OTC.Pink
10-Q: Carisma Therapeutics Announces Strategic Shift and Workforce Reduction Amidst Financial Uncertainty
Carisma Therapeutics is reducing operations and exploring strategic alternatives, including a potential wind-down, due to insufficient cash resources.
OTC.Pink
10-Q: Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Carisma Therapeutics reported a net loss of $42.8 million for the nine months ended September 30, 2024, and anticipates sufficient cash to sustain operations into the third quarter of 2025.
OTC.Pink
Carisma Therapeutics announced its Q2 2024 financial results, highlighting a strategic shift to prioritize its lead product candidate, CT-0525, and a revised operating plan to extend its cash runway.
OTC.Pink
Carisma Therapeutics announced its first quarter 2024 results, highlighting a strategic shift to prioritize its CT-0525 program and reduce operating expenses.